[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aids":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,89,117,146,172,197,226,250,273,299,322,350],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100595431","implementing-depression-and-adherence-treatment-100595431",false,"NCT07032363","Implementing Depression and Adherence Treatment","Implementing Depression and Adherence Treatment in South Africa HIV Care","Inclusion Criteria for Clinics (the primary \"participants\"):\n\n* Clinics are eligible if they provide HIV primary care via the City of Cape Town (CoCT) Department of Health\n* Clinics will be assigned to the study upon notice of funding and before start up.\n\nInclusion Criteria for Patient-level Outcomes:\n\nAlthough the unit of randomization is at the clinic level, the study will be looking at adult patient level data at each clinic. All patients engaged in care at one of the 10 primary care\u002FHIV treatment clinics in the study will be included if they:\n\n* Are 18 years of age or older and\n* Have a detectable HIV viral load (operationalized as the lower limit of detection on the standard test is used at the local clinic), or presumed detectable viral load per clinic standards\n* Screen in for depression via the PHQ (following detection standards set in clinics)\n\nExclusion Criteria:\n\n-Children below the age of 18 will not be included in the proposed study for adults.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to compare a core set and enhanced set of implementation strategies in increasing the reach of evidence-based treatments to patients with HIV and depression. The main questions it aims to answer are:\n\nWhat proportion of patients start an evidence-based treatment for depression (reach)? What percentage of patients show clinical improvement in depression and what percentage attain viral undetectability within one year (effectiveness)?\n\nResearchers will compare high and low reach clinics to further inform tailored implementation strategies for uptake and maintenance.\n\nClinics will be randomized into one of two study arms: core versus enhanced strategies. In both arms, core strategies will be utilized. Enhanced clinics will also receive more resource-intensive training.",[26,27,28,29],"Depression","HIV","Adherence, Treatment","AIDS",[31,27,32],"implementation science","depression","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2026-05-20",{"date":41,"type":20},"2030-05",{"name":43,"class":44},"University of Miami","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100561090","the-collaborative-care-prtner-study-100561090","NCT06585631","The Collaborative Care PrTNER Study","The Collaborative Care PrTNER (Prevention, Treatment, Navigation, Engagement, Resource) Project","PrTNER","Inclusion Criteria:\n\nAim 1:\n\n* 15-24 years old;\n* Cisgender male;\n* History of condomless sex;\n* Moderate-to-high risk SU behaviors based upon a Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT) score ≥2,\n* Living in Philadelphia, PA or Baltimore, MD, and surrounding areas;\n* Able to read and write in English\n\nAim 2:\n\n* 15-29 years old;\n* Cisgender male;\n* Living with a diagnosis of HIV;\n* CRAFFT score ≥2,\n* Living in Philadelphia, PA or Baltimore, MD, and surrounding areas;\n* Able to read and write in English\n\nAim 3\n\n• All randomized study participants will be included in Aim 3.\n\nExclusion Criteria:\n\nAim 2:\n\n* Participants will be excluded if they are:\n* Assigned female sex at birth\n* Identify as transgender\n* Outside the age criteria (\\\u003C15 or \\>29 years old)\n* Cognitively unable to complete study requirements\n* Living outside of the two geographic areas\n* Do not screen positive for SU\n* No prior substance use history\n* No prior condomless sex;\n* Unable to read or write in English,\n* Plan to move in the next 12 months.",true,"MALE","15 Years","29 Years",{"count":59,"type":20},275,[23],"A randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living with HIV) among young aged 15 to 29 through engagement in SU treatment.",[27,63,64,29],"Substance Use Disorders","Substance Use",[27,29,66,67,68,69,70,71,72,73,74,75,76,77,78],"Substance use","Substances use disorder","drug use","alcohol use","preexposure prophylaxis","PrEP","peer coaches","community health worker","young men","adolescents","young male","young males","adolescent males","2026-05-15",{"date":81,"type":37},"2026-05-18",{"date":83,"type":37},"2025-01-02",{"date":85,"type":20},"2028-06-30",{"name":87,"class":44},"Children's Hospital of Philadelphia",2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100639000","phase-1-efficacy-and-safety-of-immune-checkpoint-inhibitors-for-refractory-opportunistic-infections-in-aids-100639000","NCT07579247","Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS","A Study on the Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of AIDS Complicated With Refractory Opportunistic Infections","Inclusion Criteria:\n\nAge ≥ 18 years. Confirmed HIV-1 infection.\n\nMust have at least one opportunistic infection meeting the \"refractory\" criteria after currently available standard anti-infective treatment, defined as follows:\n\n1. Parvovirus B19: Hemoglobin (Hb) fails to recover (increase \\\u003C10g\u002FL) or requires transfusion maintenance, with reticulocytes persistently \\\u003C1% after 4 weeks of Intravenous Immunoglobulin (IVIG) therapy.\n2. Cytomegalovirus (CMV): Blood\u002Fbody fluid CMV-DNA decrease \\\u003C1 log10 or new\u002Fworsening organ damage after 2 weeks of Ganciclovir or Foscarnet therapy.\n3. Mpox virus: Unhealed lesions, new lesions, necrotic coalescence, or no decrease in viral load after 14 days of Tecovirimat, Cidofovir, or Brincidofovir therapy.\n4. Progressive Multifocal Leukoencephalopathy (PML): Continuous deterioration of neurological symptoms or expanded lesion area on MRI after 3 months of optimized antiretroviral therapy (ART).\n5. Pneumocystis jirovecii pneumonia (PCP): No improvement in oxygenation index or expanded radiological lesions after 8 days of adequate SMZ-TMP therapy.\n6. Cryptococcal meningitis: Persistently positive cerebrospinal fluid (CSF) culture after 4 weeks of induction therapy.\n7. Talaromyces marneffei \u002F Invasive Aspergillosis: Persistently positive culture or progression of radiological\u002Fclinical symptoms after 2 weeks of Amphotericin B or Voriconazole therapy.\n8. Mycobacterium tuberculosis (TB): Persistently positive sputum smear or culture after 2 months of standard anti-tuberculosis therapy.\n9. Nontuberculous mycobacteria (NTM): No improvement in clinical symptoms after 1 month of standard therapy, or culture not turning negative after 3 months.\n\nHigh PD-1 expression on peripheral CD8+ T cells (\\>25%) OR weak pathogen-specific ELISpot response (\\\u003C50 SFCs\u002F10\\^6 cells).\n\nAgreement to use highly effective contraception during the study and for 6 months after the end of the trial.\n\nVoluntary signing of informed consent.\n\nExclusion Criteria:\n\nHistory of active autoimmune disease or autoimmune disease requiring systemic treatment.\n\nPrior organ transplantation or hematopoietic stem cell transplantation. Pregnant or lactating women. Known allergy or anti-drug antibodies to the study drug or its excipients. Prior treatment or exposure to any other immune checkpoint inhibitors. Received immunomodulatory or immunosuppressive therapy (excluding glucocorticoids) within 24 weeks prior to the first dose of the study drug.\n\nPsychiatric disorders or substance abuse that may interfere with the trial. Other severe medical conditions deemed by the investigator as unsuitable for trial participation (e.g., uncontrolled severe heart, liver, or renal failure).",{"count":97,"type":20},50,[99,100],"PHASE1","PHASE2","This prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering from refractory opportunistic infections (OIs).\n\nDespite effective antiretroviral therapy (ART), some HIV patients develop severe, hard-to-treat infections (such as CMV, PCP, Tuberculosis, etc.) that do not respond to standard antimicrobial treatments. This is often due to a condition called \"immune exhaustion,\" where the body's infection-fighting T-cells become inactive and express high levels of a protein called PD-1.\n\nSintilimab is an immune checkpoint inhibitor that blocks PD-1, effectively \"waking up\" the exhausted T-cells. While traditionally used for cancer, recent evidence suggests it can safely restore the immune system's ability to clear stubborn infections in HIV patients. In this study, eligible patients with refractory OIs and evidence of immune exhaustion will receive Sintilimab (200 mg intravenously every 3 weeks for a total of 3 doses) alongside their regular treatments. Researchers will monitor patient safety, clinical improvement, and immunological recovery.",[27,29,103,104],"Immune Checkpoint Inhibitors","Refractory Opportunistic Infection","NOT_YET_RECRUITING","2026-05-06",{"date":108,"type":37},"2026-05-12",{"date":110,"type":20},"2026-05",{"date":112,"type":20},"2029-12",{"name":114,"class":115},"Shanghai Public Health Clinical Center","OTHER_GOV",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":45},"100467975","a-randomized-clinical-trial-to-evaluate-solutions-for-the-management-of-virologic-failure-on-tld-in-sub-saharan-africa-100467975","NCT05373758","A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on Tenofovir, Lamivudine, and Dolutegravir (TLD) in Sub-Saharan Africa","RESOLVE","Inclusion Criteria:\n\n* Age 15 years and above\n* Enrolled in HIV care at one of the study clinics\n* History of two HIV-1 RNA viral load measurements \\>1,000 copies\u002FmL while on TLD\n* On TLD for at least 12 months\n* Lives within 100 kilometers of study clinic\n\n  * Pregnant women are eligible for enrollment.\n\nExclusion Criteria:\n\n* Plans to transfer out of the clinic within the next 48 weeks\n* Plans to move out of the study catchment area within the next 48 weeks\n* As determined by chart review, we will exclude those with known virologic failure on protease inhibitors or exposure to integrase strand transfer inhibitors other than dolutegravir.",{"count":126,"type":20},648,[23],"The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to \\\u003C50 copies\u002FmL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.",[130,29,131],"HIV Infections","Virologic Failure",[133,134,135,136],"ART","Medication Adherence","Drug resistance","Dolutegravir","2026-03-17",{"date":139,"type":37},"2026-03-19",{"date":141,"type":37},"2024-02-07",{"date":143,"type":20},"2027-06-30",{"name":145,"class":44},"Massachusetts General Hospital",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100469255","screening-for-hepatitis-b-hepatitis-c-and-aids-viruses-using-dried-blood-spot-100469255","NCT05390424","Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot","BUVARD76_27","Inclusion Criteria:\n\n* Former or active intravenous and\u002For nasal drug user\n* Person on opiate substitution therapy\n\nExclusion Criteria:\n\n* Person with known active viral infection(s)",{"count":154,"type":20},500,[23],"The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users",[158,159,29],"Hepatitis B","Hepatitis C",[161],"Dried Blood Spot","2026-02-12",{"date":164,"type":37},"2026-02-17",{"date":166,"type":37},"2022-12-02",{"date":168,"type":20},"2027-01",{"name":170,"class":44},"University Hospital, Rouen",11,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":54,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100148682","the-dc-cohort-longitudinal-hiv-status-neutral-study-100148682","NCT01206920","The DC Cohort Longitudinal HIV Status Neutral Study","Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort","DC Cohort","Treatment Cohort Inclusion Criteria:\n\n* Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.\n* Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.\n* Patient is a minor who is consented by a parent or legal guardian.\n\nTreatment Cohort Exclusion Criteria:\n\n* Patient is unable or refuses to provide informed consent.\n* Minor children ages 12 through 17 who are unaware of their HIV status\n\nPrevention Cohort Inclusion Criteria:\n\nPersons receiving any antiretroviral prescription without evidence of HIV or Hepatitis B infection\n\n* PrEP (e.g., TDF\u002FFTC, Descovy, Apretude)\n* Combination ART indicative of nPEP in an HIV-uninfected person\n* Persons receiving an antiretroviral prescription indicative of DoxyPEP Doxycycline 200mg PO taken within 72 hrs of unprotected sexual encounter (or variations thereof where clearly not prescribed as a treatment course)\n* Test positive for ≥1 bacterial STI (positive gonorrhea (GC\u002FNG) or chlamydia (CT) test or positive syphilis test requiring treatment within one year)\n\n  * 2 bacterial STI (GC, chlamydia, syphilis) tests at 2 or more different encounters\n  * 2 HIV tests at 2 or more different encounters\n* Patient requesting PrEP at their clinical visit\n* Patient requesting nPEP at their clinical visit\n* People who identify as injecting drugs\n\nPatients with a Z29.81 Encounter for HIV pre-exposure prophylaxis",{"count":181,"type":20},19000,"OBSERVATIONAL","The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus\u002FAcquired Immune Deficiency Syndrome (HIV\u002FAIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.",[27,29],[27,29,186],"Co-morbidities","2026-01-29",{"date":189,"type":37},"2026-02-02",{"date":191,"type":37},"2011-01",{"date":193,"type":20},"2041-01",{"name":195,"class":44},"George Washington University",14,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":116},"100603077","the-quality-of-life-and-viral-control-effect-of-aids-patients-after-long-acting-injection-of-cabotegravir-and-rilpivirine-100603077","NCT07131826","The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine","Inclusion Criteria:\n\n18 years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire\n\nExclusion Criteria:\n\nNot clinical diagnosis of HIV infection Do not accept questionnaires","99 Years",{"count":205,"type":20},200,"\"AIDS\" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.",[208,209,210,211,29],"Viral Control","Quality of Life","Cabotegravir","Rilpivirine",[213,214,29,215,216],"cabotegravir","rilpivirine","quality of life","viral control","2025-08-17",{"date":219,"type":37},"2025-08-20",{"date":221,"type":20},"2025-08-15",{"date":223,"type":20},"2026-12-31",{"name":225,"class":44},"National Taiwan University Clinical Trial Center",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":249},"100511417","phase-1-mesenchymal-stem-cells-treatment-for-aids-patients-at-late-stage-100511417","NCT05939167","Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage","A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage","Inclusion Criteria:\n\n1. Confirmed HIV infection, aged 18-65, both genders\n2. CD4+T count less than 500 cells\u002Ful at baseline.\n3. No serious AIDS related events. 3. could understand and sign the informed consent form and comply with the requirements of this study.\n\n4\\. agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study\n\nExclusion Criteria:\n\n1. have HBV\u002FHCV\u002FHDV\u002FHEV infection, and the virological test is positive.\n2. The viral load for CMV and EBV is more than 1000 copies\u002FML.\n3. have HIV-2 infection.\n4. have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors.\n5. received treatment of hormones or other immunosuppressive drugs for a long time.\n6. with serious AIDS related or unrelated events.\n7. received immunosuppressive drugs or systemic cytotoxic drugs for more than 3 months before recruiting\n8. have poor compliance during treatment.\n9. drug addiction within 6 months, or the urine drug test is positive\n10. participate in other clinical trials currently\n11. pregnant, breastfeeding, or have fertility requirements.\n12. unable or unwilling to provide informed consents, or unable to comply with research requirements.\n13. Other serious situations that may hinder clinical trials.","65 Years",{"count":235,"type":20},150,[99,100],"The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.",[29],"2025-08-07",{"date":241,"type":37},"2025-08-12",{"date":243,"type":37},"2023-12-10",{"date":245,"type":20},"2028-07-10",{"name":247,"class":248},"Cell Energy Life Sciences Group Co. LTD","INDUSTRY",4,{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":116},"100531676","economic-navigation-and-strengthening-to-research-unrestricted-services-for-transgender-women-entrust-100531676","NCT06202898","Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)","Inclusion Criteria:\n\n* Aged ≥18 years\n* Male at birth\n* Identify as a woman\u002Ftransgender woman\n* Should not be consistently using PrEP (less than four doses per week)\n* Should not have any known allergy or adverse reaction to PrEP or the active drug tenofovir in ART. One of the goals of the study is to move more people into a PrEP program\n* Be able to speak and understand spoken English and\u002For Spanish (including persons who cannot read or write)\n* Have a smart phone that can take pictures\n\nExclusion Criteria:\n\n* Unwilling to adhere to study procedures\n* Participation in an HIV vaccine trial\n* Have a life-threatening SUD\\*\n* Any condition, that in the opinion of the study staff, would make participation in the study unsafe, or interfere with achieving the study objective such as medical conditions which prevents the use of PrEP\n* Unable to provide consent",{"count":257,"type":20},110,[23],"The overall hypothesis is that stabilizing transgender women financially while providing them tailored counselling will increase their odds of them linking to substance use services, PrEP services if they do not have HIV, and transgender women who are living with HIV will be more adherent to their ART treatment.",[261,262,263],"Transgender Women","Aids","Hiv","2024-12-03",{"date":266,"type":37},"2024-12-06",{"date":268,"type":37},"2023-07-11",{"date":270,"type":20},"2027-06",{"name":272,"class":44},"University of Central Florida",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":280,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":116},"100527290","metagenomic-next-generation-sequencing-guides-anti-infection-strategies-100527290","NCT06145841","Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies","Clinical Application of Metagenomic Next-Generation Sequencing-Guided Anti-Infection Strategies in AIDS Patients With Severe Pneumonia and\u002For Sepsis","Inclusion Criteria:\n\n1. Confirmed HIV infection;\n2. Progression to AIDS stage: CD4+ count \\\u003C200 cells\u002Ful and\u002For occurrence of AIDS opportunistic infections;\n3. Age between 18 and 65 years;\n4. Meeting the diagnosis of severe pneumonia or septic shock:\n\n   1. The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;\n   2. The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's \"Chinese Guidelines for the Emergency Treatment of Sepsis\u002FSeptic Shock (2018).\n\nExclusion Criteria:\n\n1. Coexisting central nervous system lesions, severe liver disease, or cirrhosis;\n2. Concurrent AIDS-related or unrelated tumors;\n3. Women who are pregnant or breastfeeding;\n4. Severe underlying diseases of the heart, lungs, liver, kidneys, etc.;\n5. Alcohol abuse or drug use;\n6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial.",{"count":281,"type":20},400,"This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and\u002For sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world",[29,284,285],"Pneumonia","Sepsis, Neonatal",[29,287,288,289],"severe pneumonia","Sepsis","metagenomic next-generation sequencing","2023-11-17",{"date":292,"type":37},"2023-11-24",{"date":294,"type":37},"2023-10-23",{"date":296,"type":20},"2027-10-23",{"name":298,"class":44},"Guangzhou 8th People's Hospital",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":306,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":116},"100526626","risk-identification-factors-for-pulmonary-function-impairment-in-aids-patients-recovered-from-severe-pneumonia-100526626","NCT06137196","Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia","Study on Risk Identification Factors for Lung Function Impairment in AIDS Patients Recovered From Severe Pneumonia","Inclusion Criteria:\n\n1. Confirmed HIV infection;\n2. Progression to the AIDS stage: CD4+ count \\\u003C200 cells\u002FµL and\u002For occurrence of opportunistic infections associated with AIDS;\n3. Age between 18 to 65 years;\n4. Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA).\n\nExclusion Criteria:\n\n1. Concurrent central nervous system lesions, severe liver disease, or cirrhosis;\n2. Concurrent AIDS-related or non-related tumors;\n3. Women who are pregnant or breastfeeding;\n4. Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.;\n5. Alcohol abuse or drug use;\n6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial",{"count":307,"type":20},100,"Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.",[29,284],[29,311,312,313],"Severe pneumonia","Lung function","Predictive factors","2023-11-13",{"date":316,"type":37},"2023-11-18",{"date":318,"type":37},"2023-11-01",{"date":320,"type":20},"2027-11-01",{"name":298,"class":44},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":331,"conditions":332,"keywords":336,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100519534","the-influence-of-primary-hiv-1-drug-resistance-mutations-on-immune-reconstruction-in-plwh-100519534","NCT06044792","The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH","The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in Patients Treated With Antiretroviral Drugs - an Observational Cohort Study.","Inclusion Criteria:\n\n* HIV-1 confirmed infection\n* ART naive patients \\> 18 years\n* virological suppression after 6 months of ART\n* available results of HIV genotyping before the start of ART\n\nExclusion Criteria:\n\n* hematologic neoplasms\n* use of chemotherapy, immunosuppressive drugs and other myelotoxic agents\n* lack of patient's consent to participate in the study","100 Years",{"count":97,"type":20},"Since the reasons for differential immune reconstitution in HIV-infected patients are still not fully understood, we considered it reasonable to investigate whether the presence of primary HIV drug resistance mutations could be one of the factors of inadequate immune reconstitution.\n\nEvaluation of unfavorable factors of immune reconstitution can help identify patients at risk of persistently low CD4 cell counts and CD4:CD8 ratios and requiring careful monitoring for progression to AIDS.",[263,29,333,133,334,335],"CD4 Deficiency","Treatment Resistant Disorders","Treatment-Sensitive HIV Infection",[27,337,338,339,340],"CD4","DRM","drug resistance","immune reconstruction","2023-09-17",{"date":343,"type":37},"2023-09-21",{"date":345,"type":20},"2023-09-30",{"date":347,"type":20},"2028-01-01",{"name":349,"class":44},"Medical University of Warsaw",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":357,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":116},"100515236","functional-cure-of-hepatitis-b-in-hivhbv-co-infected-patients-100515236","NCT05988879","Functional Cure of Hepatitis B in HIV\u002FHBV Co-infected Patients","A Clinical Research on Functional Cure Strategies for Hepatitis B Among HIV\u002FHBV Co-infected Patients in China","Inclusion Criteria:\n\n1. Age 18-65 years old, gender unrestricted.\n2. Meeting the People's Republic of China Health Industry Standard (WS293-2008) - \"AIDS and HIV Infection Diagnostic Criteria\", confirmed as HIV-1 infected.\n3. HBsAg positive for more than 6 months.\n4. At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg \\\u003C1000IU\u002FmL, HBeAg negative, HBV DNA \\\u003C100IU\u002Fml, CD4+T lymphocyte count \\>200 cells\u002FμL and HIV-RNA\\\u003C20 copies\u002Fml.\n\nExclusion Criteria:\n\n1. Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy.\n2. Co-infected with Hepatitis A, C, D, or E viruses.\n3. With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver.\n4. With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus.\n5. Post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment.\n6. With severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes.\n7. Excessive alcohol (average daily alcohol intake \\>40g for men, \\>20g for women) or drug users.\n8. Participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.",{"count":358,"type":20},60,"Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV\u002FHBV co-infected patients",[29,158],[362,363,364],"HIV\u002FHBV co-infection","Functional cure","Interferon","2023-08-10",{"date":367,"type":37},"2023-08-14",{"date":369,"type":37},"2023-08-02",{"date":371,"type":20},"2028-08-02",{"name":298,"class":44}]